• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

March Restructuring

Quote




anonymous said:
Nothing against Ashfield reps. Just that they aren’t needed. It’s a huge waste of money and resources for BI when we are at a time that we are trying to be financially lean,
Let’s cut bait with the contract reps. It is time. And over lapping reps just never works well.
Click to expand...
Maybe it’s the BI reps that should be looked at to be replaced. Just saying Ashfield is more economical. The HSBS and current management can handle territories
 








HSBS does not even know my customers. Really HSBS is not Not the answer here. In fact if they want to cut cost, Im certain they are getting paid more. Cut some of them too.
 




anonymous said:
Maybe it’s the BI reps that should be looked at to be replaced. Just saying Ashfield is more economical. The HSBS and current management can handle territories
Click to expand...

The Ashfield rep you are working with now may cost more than a typical BI rep. Contract sales reps are not always the cheapest, however they are the more flexible and easiest to term/eliminate.

The Customer service reps being advertised by Ashfield are cheaper than a BI rep. Keep in mind this is also less money BI pays Ashfield.

Good luck to all
 








anonymous said:
I know because BI still needs us to drum up hype for Stiolto in Q2. After that’s out of the way, then the culling starts.
Click to expand...

Not gonna lie, that sounds about right. After that, seems like a good time for some kind of mix up. Bi didn't learn and is paying the price. We have 3 disease states. Metabolic, Respiratory and Cardio. 2 of the 3 are going to be fairly worthless in a few years. Look at our pipeline. We have absolutely nothing coming out anytime soon. 3-4 years at the very least for anything other than expanded indications. But oh yeah, vision 2025. 20 Billion dollars in sales worldwide, by then. One TINY problem. You need products to sell. We won't have any. Thank god we didn't get a triple in COPD. That really saved us.
 




anonymous said:
Not gonna lie, that sounds about right. After that, seems like a good time for some kind of mix up. Bi didn't learn and is paying the price. We have 3 disease states. Metabolic, Respiratory and Cardio. 2 of the 3 are going to be fairly worthless in a few years. Look at our pipeline. We have absolutely nothing coming out anytime soon. 3-4 years at the very least for anything other than expanded indications. But oh yeah, vision 2025. 20 Billion dollars in sales worldwide, by then. One TINY problem. You need products to sell. We won't have any. Thank god we didn't get a triple in COPD. That really saved us.
Click to expand...
Let's clarify "other than expanded indications". The Jardiance CV data for CHF is for real and that is a very large market. There are clinical trials going on presently across the country. To be fair Farxiga has similar data and is also doing clinical trials for CHF. Keep in mind that the CV marketplace is much,much bigger than diabetes. There are no guarantees but a CHF indication is very possible within 2 years. Will this be enough to offset Pradaxa and Spiriva going off patent? Probably not but one could see a CV/metabolic sales force in the future.
 




anonymous said:
Let's clarify "other than expanded indications". The Jardiance CV data for CHF is for real and that is a very large market. There are clinical trials going on presently across the country. To be fair Farxiga has similar data and is also doing clinical trials for CHF. Keep in mind that the CV marketplace is much,much bigger than diabetes. There are no guarantees but a CHF indication is very possible within 2 years. Will this be enough to offset Pradaxa and Spiriva going off patent? Probably not but one could see a CV/metabolic sales force in the future.
Click to expand...

Without question all of that is true. But without question, there would still be a need for reduction in headcount. Can't have the entire company selling jardiance.
 








anonymous said:
Without question all of that is true. But without question, there would still be a need for reduction in headcount. Can't have the entire company selling jardiance.
Click to expand...
Agree. The problem is if they throw all reps into big pool and do cuts based on ranking, where you live etc. That's what happened a few years ago in respiratory but in that scenario specialty reps bounced PCP.
 








Hot off the press: Hand over your Humira biosim launch plans, judge tells Boehringer in AbbVie patent fight

This would create a LOT of sales jobs. Humira is 6 Billion $ drug. All depends on the judge now...
 












Ha BI couldn’t sell a biologic / bio similar! Not saying the sales people aren’t competent just any real leadership left in large molecule BIPi Pharma has left the building.
This company can ruin a wet dream!
They lucked into profits back in the day and their luck has run out
 




















Top Bottom
Back
Quote